Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BY 4.0ACS Omega

Phenethylamine-Derived β-Lactam Derivatives as Antibacterial Leads against Respiratory Pathogens: In Vitro Evaluation, Cytotoxicity Profiling, and In Silico Insights

  1. 1Erzurum Technical University , , ,
  2. 2Ataturk University , , ,
  3. 3Dokuz Eylul University , , ,

Abstract

Secondary pulmonary bacterial infections represent a severe clinical complication in lung cancer management, necessitating effective antibacterial strategies. In this study, a series of phenethylamine-derived imines (1–6) and their cyclized β-lactam derivatives (7–12) were systematically evaluated as prospective antibacterial leads against respiratory pathogens (Klebsiella pneumoniae and Streptococcus pneumoniae), alongside cytotoxicity profiling in A549 human lung cells. Phenotypic antibacterial assays showed that open-chain imine precursors (1–6) had no discernible activity, whereas core cyclization into β-lactam derivatives (7–12) conferred antibacterial activity (MIC: 12.5–50 μM), including activity against K. pneumoniae, which showed no inhibition zone with ampicillin. Compounds 7 and 11 had the lowest MICs against K. pneumoniae (12.5 μM). Comparing MIC values with A549 cytotoxicity gave an in vitro selectivity index (SI) of >16 for compound 7 against K. pneumoniae. This is a censored lower bound (A549 IC50 > 200 μM) that reflects low cytotoxicity in a lung cell line and does not indicate cancer selectivity. Preliminary molecular docking against bacterial penicillin-binding proteins (PBPs) and human MDM2 gave scores that differed little among compounds and did not follow the MIC values, so they are treated here as exploratory only. Overall, these findings identify phenethylamine-derived β-lactams as a scaffold for antibacterial lead development that warrants further mechanistic investigation and testing in noncancerous lung cells.

Related

  1. Design, synthesis and dual anticancer and antibacterial evaluation of novel 1,3,4-oxadiazole-2-thiol derivatives targeting EGFR and DNA Gyrase B: integrated docking, DFT and ADMET studies
    Ila M. Ram, Jay B. Maheta, Darshna K. Lakhnotra +6
    Future Medicinal ChemistryPeer-reviewedLicence not statedFull textOrganic chemistryPMC
  2. Synthesis, Antioxidant Activity, In Silico Evaluation, and Cytotoxicity of Novel Polyphenolic–Methyliden–Hydrazono–Thiazole Derivatives
    Alexandra Cătălina Cornea, Gabriel Marc, Ionel Fizeșan +9
    MoleculesPeer-reviewedCC BY 4.0Full textOrganic chemistryCrossrefEurope PMC
  3. Synthesis, Biological Evaluation, and Molecular Dynamics Studies of Novel 1,2,4-Triazole-Functionalized Benzene-Sulfonate Derivatives as Potential Enzyme Inhibitors and Cytotoxicity in HepG2 Cells.
    Yasemin Ünver, Fikret Türkan, Halil İbrahim Güler +3
    Pharmaceuticals (Basel, Switzerland)Peer-reviewedCC BYFull textOrganic chemistryEurope PMC
  4. Synthesis, RSM-based optimization, biological evaluation, and molecular modeling of novel (R)-carvone-derived isoxazole derivatives as antibacterial agents
    Nora M Farhan, Rawiyah A Alkahtani, Jehan Y Al-Humaidi +5
    RSC advancesPeer-reviewedCC BY-NCFull textOrganic chemistryEurope PMCEurope PMCPMC
  5. Novel Carbazole–Acylthiourea Derivatives: Synthesis, Antimicrobial, Antioxidant, Hemocompatibility, Cytotoxicity, and ADME‐Tox Profiling
    Carmen Limban, Ioana Cristina Marinaş, Mariana Carmen Chifiriuc +15
    ChemistryOpenPeer-reviewedCC BYFull textOrganic chemistryEurope PMCCrossref
BibTeX
@article{yildirim2026phenethylaminederived,
  title = {{Phenethylamine-Derived β-Lactam Derivatives as Antibacterial Leads against Respiratory Pathogens: In Vitro Evaluation, Cytotoxicity Profiling, and In Silico Insights}},
  author = {Merve Yildirim and Elif Aksakal and Taha Yasin Bayram and Eda Irmak and Harun Gun and Bunyamin Ozgeris and Arzu Gormez},
  journal = {ACS Omega},
  year = {2026},
  month = nov,
  doi = {10.1021/acsomega.6c06993},
  url = {https://pubs.acs.org/acsodf/article/doi/10.1021/acsomega.6c06993/5469609/Phenethylamine-Derived-Lactam-Derivatives-as},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Phenethylamine-Derived β-Lactam Derivatives as Antibacterial Leads against Respiratory Pathogens: In Vitro Evaluation, Cytotoxicity Profiling, and In Silico Insights
AU  - Merve Yildirim
AU  - Elif Aksakal
AU  - Taha Yasin Bayram
AU  - Eda Irmak
AU  - Harun Gun
AU  - Bunyamin Ozgeris
AU  - Arzu Gormez
PY  - 2026
DA  - 2026/11/12
JO  - ACS Omega
DO  - 10.1021/acsomega.6c06993
UR  - https://pubs.acs.org/acsodf/article/doi/10.1021/acsomega.6c06993/5469609/Phenethylamine-Derived-Lactam-Derivatives-as
AB  - Secondary pulmonary bacterial infections represent a severe clinical complication in lung cancer management, necessitating effective antibacterial strategies. In this study, a series of phenethylamine-derived imines (1–6) and their cyclized β-lactam derivatives (7–12) were systematically evaluated as prospective antibacterial leads against respiratory pathogens (Klebsiella pneumoniae and Streptococcus pneumoniae), alongside cytotoxicity profiling in A549 human lung cells. Phenotypic antibacterial assays showed that open-chain imine precursors (1–6) had no discernible activity, whereas core cyclization into β-lactam derivatives (7–12) conferred antibacterial activity (MIC: 12.5–50 μM), including activity against K. pneumoniae, which showed no inhibition zone with ampicillin. Compounds 7 and 11 had the lowest MICs against K. pneumoniae (12.5 μM). Comparing MIC values with A549 cytotoxicity gave an in vitro selectivity index (SI) of >16 for compound 7 against K. pneumoniae. This is a censored lower bound (A549 IC50 > 200 μM) that reflects low cytotoxicity in a lung cell line and does not indicate cancer selectivity. Preliminary molecular docking against bacterial penicillin-binding proteins (PBPs) and human MDM2 gave scores that differed little among compounds and did not follow the MIC values, so they are treated here as exploratory only. Overall, these findings identify phenethylamine-derived β-lactams as a scaffold for antibacterial lead development that warrants further mechanistic investigation and testing in noncancerous lung cells.
SN  - 2470-1343
ER  -